The role of nutrients and probiotics in treatment of depression
N. G. Neznanov,
G. V. Rukavishnikov,
E. D. Kasyanov,
M. A. Ganzenko,
L. V. Leonova,
T. V. Zhilyaeva,
G. E. Mazo https://doi.org/10.20538/1682-0363-2021-4-171-179
Abstract
Currently, a growing amount of data is emerging on the role of various environmental factors (nutrients, gut microbiota, etc.) on formation of depression. The impact on these factors can be effective not only in treatment of major depressive disorder, but also in its early prevention. Therefore, a more detailed study of environmental factors in depression can lead both to a better understanding of the etiology and pathogenesis of the disorder and to optimization of approaches to its treatment. The aim of the review was to assess the potential role of a number of environmental factors associated with nutritional aspects and characteristics of individual microflora, as well as to review the prospects of a strategy for affecting these factors in treatment and prevention of depression.
About the Authors
N. G. Neznanov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology;
I.P. Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
3, Bekhtereva Str., St. Petersburg, 192019;
6/8, Lva Tolstogo Str., St. Petersburg, 197022
G. V. Rukavishnikov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3, Bekhtereva Str., St. Petersburg, 192019
E. D. Kasyanov
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
M. A. Ganzenko
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3, Bekhtereva Str., St. Petersburg, 192019
L. V. Leonova
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3, Bekhtereva Str., St. Petersburg, 192019
T. V. Zhilyaeva
Privolzhsky Research Medical University
Russian Federation
Russian Federation
10/1, Minina and Pozarskogo Sq., Nizhny Novgorod, 603005
G. E. Mazo
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3, Bekhtereva Str., St. Petersburg, 192019
References
1. URL: https://www.who.int/news-room/fact-sheets/detail/depression
2. Ionescu D., Papakostas G. Experimental medication treatment approaches for depression. Transl. Psychiatry. 2017; 7 (3): e1068. DOI: 10.1038/tp.2017.33.
3. Sparling T.M., Henschke N., Nesbitt R.C., Gabrysch S. The Role of Diet and Nutritional Supplementation in Perinatal Depression: a Systematic Review. Matern. Child Nutr. 2017; 13 (1): 10.1111/mcn.12235. DOI: 10.1111/mcn.12235.
4. Huang R., Wang K., Hu J. Effect of Probiotics on Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2016; 8 (8): pii: E483. DOI: 10.3390/nu808048331.
5. Naderi N., House, J.D. Recent Developments in Folate Nutrition. Adv. Food Nutr. Res. 2018; 83: 195–213. DOI: 10.1016/bs.afnr.2017.12.006
6. Fava M., Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J. Clin. Psychiatry. 2009; 70 (5): 12–17. DOI: 10.4088/JCP.8157su1c.03.
7. Resler G., Lavie R., Campos J. et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008; 15 (3): 145– 152. DOI: 10.1159/000151527.
8. Касьянов Е.Д., Мазо Г.Э. Нарушения одноуглеродного обмена при терапевтически резистентных депрессиях: два семейных клинических случая. Фармакогенетика и фармакогеномика. 2019; 2: 43–43. DOI: 10.24411/2588-0527-2019-10064.
9. Papakostas G.I., Shelton R.C., Zajecka J.M., et al. Effect of adjunctivel-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype. The Journal of Clinical Psychiatry. 2014; 75 (8): 855–863. DOI: 10.4088/jcp.13m08947.
10. Wilson L.R., Tripkovic L., Hart K.H., Lanham-New S.A. Vitamin D deficiency as a public health issue: using vitamin D2 or vitamin D3 in future fortification strategies. Proc. Nutr. Soc. 2017; 76 (3): 392–399. DOI: 10.1017/S0029665117000349
11. Депрессия и риск развития соматических заболеваний: руководство для врачей; под ред. Н.Г. Незнанова, Г.Э. Мазо, А.О. Кибитова. М.: Специальное издательство медицинских книг, 2018: 248.
12. Дорофейков В.В., Петрова Н.Н., Задорожная М.С. Диагностическое и прогностическое значение определения витамина D(OН) в сыворотке крови при депрессии. Медицинский алфавит. 2018; 2 (17): 47–52.
13. Li G., Mbuagbaw L., Samaan Z., Zhang S., Adachi J.D., Papaioannou A., Thabane L. Efficacy of vitamin D supplementation in depression in adults: a systematic review protocol. Syst. Rev. 2013;2: 64. DOI: 10.1186/2046-4053-2-64.
14. Amini S., Amani R., Jafarirad S., Cheraghian B., Sayyah M., Hemmati A.A. The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial. Nutr. Neurosci. 2020; Online ahead of print: 1–11. DOI: 10.1080/1028415X.2019.1707396.
15. Bertone-Johnson E.R., Powers S.I., Spangler L. et al. Vitamin D supplementation and depression in the women’s health initiative calcium and vitamin D trial. Am. J. Epidemiol. 2012; 176 (1): 1–13. DOI: 10.1093/aje/kwr482.
16. Gowda U., Mutowo M.P., Smith B.J., Wluka A.E., Renzaho A.M. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. Nutrition. 2015; 31 (3): 421–429. DOI: 10.1016/j.nut.2014.06.017.
17. Васьковский В.Е., Горбач Т.А., Есипов А.В., Светашев В.И., Яцкова М.А. Препараты омега-3 жирных кислот и их применение в медицине. Тихоокеанский медицинский журнал. 2010; 40 (2): 15–19.
18. Rapaport M.H., Nierenberg A.A., Schettler P.J. et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol. Psychiatry. 2016; 21 (1): 71–79. DOI: 10.1038/mp.2015.22.
19. Peet M., Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry. 2002; 59 (10): 913–919. DOI: 10.1001/archpsyc.59.10.913.
20. Ginty A.T., Conklin S.M. Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial. Psychiatry Res. 2015; 229 (1-2): 485– 489. DOI: 10.1016/j.psychres.2015.05.072.
21. Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry. 2011; 72 (12): 1577–1584. DOI: 10.4088/JCP.10m06634.
22. Кострюкова Е.С., Алифирова В.М., Жукова Н.Г. и др. Обонятельная дисфункция и изменение микробиоты как ранние немоторные проявления болезни Паркинсона. Бюллетень сибирской медицины. 2016; 15 (5): 66–74. DOI: 10.20538/1682-0363-2016-5-66-74.
23. Cussotto S., Sandhu K.V., Dinan T.G., Cryan J.F. The neuroendocrinology of the microbiota-gut-brain axis: A behavioural perspective. Front. Neuroendocrinol. 2018; 51: 80–101. DOI: 10.1016/j.yfrne.2018.04.002.
24. Carabotti M., Scirocco A., Maselli M.A., Severi C. The gutbrain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 2015; 28 (2): 203–209.
25. Ferrer M., Méndez-García C., Rojo D., Barbas C., Moya A. Antibiotic use and microbiome function. Biochem. Pharmacol. 2017; 134: 114–126. DOI: 10.1016/j.bcp.2016.09.007.
26. Blaser M.J. Antibiotic use and its consequences for the normal microbiome. Science. 2016; 352 (6285): 544–545. DOI: 10.1126/science.aad9358.
27. Morgun A., Dzutsev A., Dong X., et al. Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut. 2015; 64 (11): 1732–1743. DOI: 10.1136/ gutjnl-2014-308820.
28. Champagne-Jorgensen K., Kunze W.A., Forsythe P., Bienenstock J., McVey Neufeld K.A. Antibiotics and the nervous system: More than just the microbes? Brain Behav. Immun. 2019; 77: 7–15. DOI: 10.1016/j.bbi.2018.12.014.
29. Savitz J., Preskorn S., Teague T.K., Drevets D., Yates W., Drevets W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2 x 2 clinical trial. BMJ Open. 2012; 2 (1): e000643. DOI: 10.1136/bmjopen-2011-000643.
30. Khalesi S., Bellissimo N., Vandelanotte C., Williams S., Stanley D., Irwin C. A review of probiotic supplementation in healthy adults: helpful or hype? Eur. J. Clin. Nutr. 2019; 73 (1): 24–37. DOI: 10.1038/s41430-018-0135-9.
31. Dinan T.G., Stanton C., Cryan J.F. Psychobiotics: a novel class of psychotropic. Biol. Psychiatry. 2013; 74 (10): 720– 726. DOI: 10.1016/j.biopsych.2013.05.001.
32. Liu R.T., Walsh R.F.L., Sheehan A.E. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials. Neurosci. Biobehav. Rev. 2019; 102: 13–23. DOI: 10.1016/j.neubiorev.2019.03.023.
33. Ng Q.X., Peters C., Ho C.Y.X, Lim D.Y., Yeo W.S. A meta-analysis of the use of probiotics to alleviate depressive symptoms. J. Affect. Disord. 2018; 228: 13–19. DOI: 10.1016/j.jad.2017.11.063.
34. Butler M.I., Mörkl S., Sandhu K.V., Cryan J.F., Dinan T.G. The gut microbiome and mental health: what should we tell our patients? Can. J. Psychiatry. 2019; 64 (11): 747–760. DOI: 10.1177/0706743719874168.
35. Kelly J.R., Allen A.P., Temko A. et al. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain Behav. Immun. 2017; 61: 50–59. DOI: 10.1016/j.bbi.2016.11.018.
36. Okubo R., Koga M., Katsumata N. et al. Effect of bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: A proof-of-concept study. J. Affect. Disord. 2019; 245: 377–385. DOI: 10.1016/j.jad.2018.11.011.
37. Flowers S.A., Baxter N.T., Ward K.M. et al. Effects of atypical antipsychotic treatment and resistant starch supplementation on gut microbiome composition in a cohort of patients with bipolar disorder or schizophrenia. Pharmacotherapy. 2019; 39 (2): 161–170. DOI: 10.1002/phar.2214.
38. Sanchez-Villegas A., Martínez-González M.A. Diet, a new target to prevent depression? BMC Med. 2013; 11: 3. DOI: 10.1186/1741-7015-11-3.
Review
For citations:
Neznanov N.G., Rukavishnikov G.V., Kasyanov E.D., Ganzenko M.A., Leonova L.V., Zhilyaeva T.V., Mazo G.E. The role of nutrients and probiotics in treatment of depression. Bulletin of Siberian Medicine. 2021;20(4):171-179. https://doi.org/10.20538/1682-0363-2021-4-171-179
Views:
584
Email this article 